We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amarin Corp | LSE:AMRN | London | Ordinary Share | GB00B29VL935 | ORD 50P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
- |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
- | O | 0 | 92.50 | GBX |
Amarin (AMRN) Share Charts1 Year Amarin Chart |
|
1 Month Amarin Chart |
Intraday Amarin Chart |
Date | Time | Title | Posts |
---|---|---|---|
17/10/2013 | 13:43 | Amarin - set to double/treble by summer 2014 (NASDAQ:AMRN) | 16 |
02/1/2012 | 22:35 | AMARIN CORP - charts and discussion | 183 |
30/4/2007 | 11:54 | GET IN NOW OR MISSOUT | - |
12/3/2007 | 21:01 | AMARIN CORP - charts and discussion | - |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
Top Posts |
---|
Posted at 11/8/2013 18:36 by someuwin Leerink maintains Outperform on Amarin* Leerink Swann maintains its Outperform rating on shares of Amarin (AMRN) following the company's Q2 report. * Analyst Joseph Schwartz expects "approval of Vascepa for mixed-dyslipidemia" come December 20 (the PDUFA date). * Price target is nonetheless adjusted down to $18 from $20. |
Posted at 15/7/2013 20:04 by someuwin "3 Biotech Stocks That Could Double by Next Summer1. Amarin (NASDAQ: AMRN ) Amarin's stock has dropped like a sinking fastball over the past year. Shares are down more than 60% since last summer and around 30% year-to-date. The steep decline stems largely from Amarin tackling commercialization of Vascepa on its own. At least at first glance, the odds that shares could double by next summer seem slim at best. What looking at the stock's chart doesn't reveal, though, is that Amarin expects a huge decision by the Food and Drug Administration by Dec. 20. The FDA will determine whether the company's highly concentrated fish oil drug Vascepa can be marketed for treating patients with high triglyceride levels between 200 mg/dL and 499 mg/dL. Amarin already won regulatory approval for selling Vascepa for super-high triglyceride levels of 500 mg/dL and above. However, the potential market size that would open up if the FDA grants approval in December is 10 times the size of the company's market available currently. The average analysts' price target for Amarin, according to Thomson/First Call, is $16.50 -- more than triple the stock's price now." Company website: |
Posted at 20/10/2009 21:47 by lbo Recommendation; ReduceClosing Price: $1.64 |
Posted at 22/2/2008 10:40 by grahambr Check out AMRN on NASDAQ and you will see RNS 25/1/2008 not shown over here. Recommended as a speculative buy target $7. |
Posted at 03/9/2007 15:39 by grahambr Mystery as to why the price is rising, maybe we were low on the bid and are now inline with USA which seems to have traded quite alot recently. |
Posted at 18/6/2007 09:16 by seangwhite Elan's share price is steaming ahead these days, though this lot could have a long time to wait for similar share price rises I think. |
Posted at 05/6/2007 13:40 by lbo Amarin raises nearly 3m through issueTuesday June 05 2007 AMARIN, whose share price collapsed in April after its Miraxion treatment for Huntington's disease failed to show any significant benefits in trials, has raised $3.7m (2.7m) through the sale of shares and warrants. An affiliate of former shareholder Southridge Capital Management invested $3m, with Amarin directors stumping up the remaining $700,000. The company said it has placed 6.16m ordinary shares, priced at Amarin's closing price on the Nasdaq last Thursday of 60c. The investors also received warrants to purchase 0.6m shares at an exercise price of 72c. The number of new shares represents 5pc of Amarin's existing number of shares outstanding. Agreement In addition, Amarin has entered into an agreement that allows it to draw down on up to $15m of additional equity funding by Southridge over the next three years. Amarin was founded by former Elan finance director Tom Lynch, who owns 18pc of the company. The company said last month that it had built up a "valuable" development pipeline for new drugs, despite the Miraxion disappointment. Chief executive Rick Stewart said the company intended to develop this pipeline for the treatment of Parkinson's Disease, epilepsy seizures and other central nervous system disorders. Trials "The completion of this funding enables us to pursue the development of our four key programmes, three of which could potentially be in Phase II trials next year," said Stewart. Drugs must go through three phases of clinical trials before a filing can be made for regulatory approval. Amarin is quoted on the Dublin marlet and also on the screen bases NASDAQ market in New York. |
Posted at 11/5/2007 13:30 by lbo Amarin facing Nasdaq delisting on low trading price CLINICAL research firm Amarin, which was founded by former Elan finance director Tom Lynch, has warned that it may be delisted from the Nasdaq stock exchange. In its 2006 annual report, the company said that because its stock has been trading under the $1 level following its share price collapse last month, under US exchange rules after a certain period Amarin can be delisted at that level. The company's share price collapsed last month after trials of its Miraxion treatment for Huntington's disease failed to show any significant benefits. According to the annual report, Nasdaq rule 4320 states that a failure to meet the minimum bid price shall lead to a delisting after a certain period of time. Shares in Amarin were down over 5pc on Nasdaq yesterday at 62.5¢. The annual report also warned that the company has a history of losses and may not be able to attain profitability in the foreseeable future. It also said that historical financial results do not form an accurate basis for assessing its current business. It also warned shareholders that it may have to issue additional equity, leading to dilution of shares, and also said that if it cannot find additional capital resources, it will have difficulty in operating as a going concern and growing its business. Amarin shares slumped over 80pc on Nasdaq last month, with the slump coming just days after a number of brokers had upgraded the stock based on the potential success of Miraxion. The collapse was bad news for a number of high net-worth Amarin backers, including chairman Mr Lynch, Ryanair founder Tony Ryan and financier Dermot Desmond. Yesterday, Amarin said that its first-quarter operating loss widened to $9.7m from $6.6m due to higher research and development costs and non-cash share-based compensation expenses. The company said its R&D expenses for the quarter rose to $4.38m compared with $2.79m, due to the costs of the two Phase III trials with Miraxion in Huntington's disease. However, net loss narrowed to $8.8m against a loss of $9m in the year-ago period. As at March 31, 2007, Amarin had cash balances of $29m. According to the annual report, Tom Lynch's total pay package was $482,000 compared with $250,000 in 2005. Chief executive Rick Stewart was paid a total of $815,000, while Alan Cooke, chief financial officer, got $464,000. |
Posted at 28/4/2007 11:10 by lbo All confidence by investors and the brokers is now gone in the guys who were involved in Elan and now Amarin IMHO. "There were also some bitter pills to be swallowed by followers of the pharma sector. Elan lost 5pc to 10.28 as a disappointing uptake of the group's multiple sclerosis treatment Tysabri, which was relaunched last year, led to the company posting a wider-than-expected first quarter loss of $93m. But Elan's woes pale in comparison to Amarin's 80pc share price collapse after it said that its pipeline Huntington's disease drug Miraxion had failed in two late stage trials. The news was all the more shocking following a decent run by the stock, particularly in light of broker upgrades from Davy Stockbrokers and Goodbody Stockbrokers in recent weeks amid high hopes for the drug" |
Posted at 26/4/2007 15:39 by patricktrfc Well hopefully looks like we have bottomed out , although very thin trading today. The share price has gone from £2.10 to 42p in 48 hours, the slightest sign of any good news, (eg data review of trials reveals hope, a new product etc) and would expect 100% up from here so happy to hold, although it isn;t a day traders share. With the other products they have, a senior Pfizer man as head of R&D and backers including Dermot Desmond, I see significant upside next month, even just as a rebound. P |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions